The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Fas Counterattack In Vivo: Apoptotic Depletion of Tumor-Infiltrating Lymphocytes Associated with Fas Ligand Expression by Human Esophageal Carcinoma
Abstract
Various cancer cell lines express Fas ligand (FasL) and can kill lymphoid cells by Fas-mediated apoptosis in vitro. FasL expression has been demonstrated in several human malignancies in vivo. We sought to determine whether human esophageal carcinomas express FasL, and whether FasL expression is associated with increased apoptosis of tumor-infiltrating lymphocytes (TIL) in vivo, thereby contributing to the immune privilege of the tumor. Using in situ hybridization and immunohistochemistry, respectively, FasL mRNA and protein were colocalized to neoplastic esophageal epithelial cells in all esophageal carcinomas (squamous, n = 6; adenocarcinoma, n = 2). The Extent of FasL expression was variable, with both FasL-positive and FasL-negative neoplastic regions occurring within tumors. TIL were detected by immunohistochemical staining for the leukocyte common Ag, CD45. FasL expression was associated with a mean fourfold depletion of TIL when compared with FasL-negative areas within the same tumors (range 1.6- to 12-fold, n = 6, p < 0.05). Cell death of TIL was detected by dual staining of CD45 (immunohistochemistry) and DNA strand breaks (TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). There was a mean twofold increase in detectable cell death among TIL in FasL-positive areas compared with FasL-negative areas (range 1.6- to 2.4-fold, n = 6, p < 0.05). In conclusion, we demonstrate a statistically significant, quantitative reduction of TIL concomitant with significantly increased TIL apoptosis within FasL-expressing areas of esophageal tumors. Our findings suggest Fas-mediated apoptotic depletion of TIL in response to FasL expression by esophageal cancers, and provide the first direct, quantitative evidence to support the Fas counterattack as a mechanism of immune privilege in vivo in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rising incidence of adenocarcinoma of the esophagus and gastric cardia
Blot, W. J. (1991) · JAMA · doi:10.1001/jama.265.10.1287 · Cited by 2,354
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Fas ligand mediates activation-induced cell death in human T lymphocytes.
Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., & Lynch, D. H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.71 · Cited by 934
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Self-citationKang, S.-M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., & Baekkeskov, S. (1997) · Nature Medicine · doi:10.1038/nm0797-738 · Cited by 450
Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice
Lau, H. T., Yu, M., Fontana, A., & Stoeckert, C. J. (1996) · Science · doi:10.1126/science.273.5271.109 · Cited by 445
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V, Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119273 · Cited by 398
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer
Ropponen, K. M., Eskelinen, M. J., Lipponen, P. K., Alhava, E., & Kosma, V.-M. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199707)182:3<318::aid-path862>3.0.co;2-6 · Cited by 398
Human lung carcinomas express Fas ligand.
Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D., Green, D. R., & Kratzke, R. A. (1997) · PubMed · Cited by 395
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X., & Ferguson, T. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119173 · Cited by 367
Allison, J., Georgiou, H. M., Strasser, A., & Vaux, D. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3943 · Cited by 366
Vieta Rebozo, A. (1953) · PubMed · Cited by 318
Antitumor effect of locally produced CD95 ligand
Seino, K.-I., Kayagaki, N., Okumura, K., & Yagita, H. (1997) · Nature Medicine · doi:10.1038/nm0297-165 · Cited by 312
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., & Takahashi, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6420 · Cited by 252
Korbutt, G. S., Elliott, J. F., & Rajotte, R. V. (1997) · Diabetes · doi:10.2337/diab.46.2.317 · Cited by 229
Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
Zhang, H., Yang, Y., Horton, J. L., Samoilova, E. B., Judge, T. A., Turka, L. A., Wilson, J. M., & Chen, Y. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119726 · Cited by 199
Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells.
Daniel, P. T., & Krammer, P. H. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.12.5624 · Cited by 176
Nagata, S. (1996) · Nature Medicine · doi:10.1038/nm1296-1306 · Cited by 119
Inhibition of the alloantibody response by CD95 ligand
Arai, H., Chanz, S. Y., Bishop, D. K., & Nabel, G. J. (1997) · Nature Medicine · doi:10.1038/nm0897-843 · Cited by 81
O'Mahony, A. M., O’Sullivan, G. C., O’Connell, J., Cotter, T. G., & Collins, J. K. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.9.4847 · Cited by 68
Self-citationThe Fas Counterattack: A Molecular Mechanism of Tumor Immune Privilege
O’Connell, J., Bennett, M., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1997) · Molecular Medicine · doi:10.1007/bf03401808 · Cited by 63
Self-citationMulder, W. M. C., Bloemena, E., Stukart, M. J., Kummer, J. A., Wagstaff, J., & Scheper, R. J. (1997) · Gut · doi:10.1136/gut.40.1.113 · Cited by 59
FasL — Too much of a good thing?
Lau, H., & Stoeckert, C. (1997) · Nature Medicine · doi:10.1038/nm0797-727 · Cited by 45
O’Sullivan, G. C., Corbett, A. R., Shanahan, F., & Collins, J. K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.10.4717 · Cited by 41
Self-citationKirby, R. A., & Pollak, A. (1997) · Journal of Molecular Modeling · doi:10.1007/s008940050040 · Cited by 29
Cited by
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Reed, J. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64779-7 · Cited by 1,288
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Metadata
- Authors
- Bennett, M. W., O’Connell, J., O’Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., & Shanahan, F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-06-01
- Volume
- 160
- Issue
- 11
- Pages
- 5669-5675
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1915589840
- Cited by
- 326
- References
- 29
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.